Enveda Raises $311M at $2B Valuation to Push AI-Found Natural Drugs Into the Clinic
Enveda has raised a $311 million Series E at a $2 billion valuation. The round was led by Catalio Capital Management, with Iconiq participating. The financing was reported on Sept. 23, 2026. TechCrunch
The $2 billion valuation doubles what the company was worth 12 months ago. Enveda is a clinical-stage biotechnology startup, meaning it has drug candidates in human testing but no approved product yet. Yahoo Finance It was founded in 2019 by Viswa Colluru, who was an early employee of Recursion Pharmaceuticals before founding Enveda.
Enveda uses AI to discover new drugs from plants and microbes. The premise is old in pharma. Nearly half of all medicines taken in pill form start from a molecule found in nature, according to the company. Enveda The technical problem has always been search. Nature produces a huge diversity of chemistry, like a vast library with no catalog, and isolating an active structure, measuring its activity and turning it into a manufacturable drug is slow work.
Enveda is now testing several AI-discovered candidates in human clinical trials, including one targeting severe skin conditions. A separate candidate is designed to help maintain weight loss after stopping GLP-1s, the class of diabetes and weight-loss drugs. On Aug. 18, 2026, the company reported positive Phase 1 results, the earliest safety testing in people, for ENV-308, described as the "first pill designed from the chemistry of exercise." Enveda
The broader context here is familiar to anyone who has tracked AI in drug discovery. Discovery is cheap to claim and expensive to prove. Models can propose and rank candidates at machine speed. None of that matters until candidates clear toxicology, the required safety checks, and show activity in people. Enveda matters to specialists because it has moved past computer-only, or in silico, claims into multiple human programs. That transition is where many platforms stall.
Looking at what this means for the company, capital is the enabler and the constraint. A $311 million raise allows parallel clinical work instead of testing one drug at a time. It also buys time to make the discovery loop more industrial while the lead programs read out. Investors doubling the valuation in a year are pricing clinical execution, not just platform potential. The risk profile is unchanged. Early success does not predict later efficacy, and dermatology, metabolic maintenance and other indications each carry distinct regulatory and commercial paths.
In my view, the portfolio choice is pragmatic. A severe skin program offers a relatively clear clinical endpoint and a route to differentiated data. A weight-maintenance program adjacent to GLP-1s addresses a problem physicians and patients already understand, persistence of benefit after discontinuation. ENV-308 points to a third vector, translating observed human physiology into an oral candidate. If any one of those threads produces durable human data, the underlying search engine becomes much easier to value. Until then, the story is capital, clinic and cadence. The long arc remains constructive. Better search tools for natural chemistry should expand the set of druggable ideas, provided the industry judges them by human results.
